XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
3 Months Ended
Oct. 03, 2018
USD ($)
Target
Obligation
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues   $ 27,439,000 $ 21,303,000  
Deferred revenue   108,652,000   $ 111,055,000
Collaboration and License agreements        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Initial transaction price $ 252,700,000      
JJDC | Common Stock Purchase Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Oct. 03, 2018      
Proceeds from the issuance of common stock $ 75,000,000.0      
Janssen | Collaboration and License agreements        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Cash received as due under collaboration agreement 175,000,000.0      
Janssen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Development, regulatory and sales milestones payments   6,200,000,000    
Milestone payment $ 70,000,000.0      
Janssen | License Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Oct. 03, 2018      
Janssen | License Agreement | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Development, regulatory and sales milestones payments $ 1,600,000,000      
Janssen | Research Collaboration and Option Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Oct. 03, 2018      
Number of additional targets for development, regulatory and sales milestone payments | Target 3      
Janssen | Collaboration Agreement | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Development, regulatory and sales milestones payments $ 1,900,000,000      
Janssen | JNJ-3989 (ARO-HBV) Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Milestone payment $ 25,000,000.0      
Number of distinct performance obligations | Obligation 1      
Revenues   0 12,700,000  
Contract assets   0    
Deferred revenue   0    
Janssen | JNJ-75220795 (ARO-JNJ1)        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues   0 $ 300,000  
Contract assets   0    
Deferred revenue   $ 0